



In the management of acute severe


**ASTHMA**



**CRITLIN 1.25**

Levosalbutamol & Ipratropium Bromide Respirator Solution

**R E S P U L E S**



- Levosalbutamol compared to racemic salbutamol has better efficiency and safety profile
- Levosalbutamol sulphate is a relatively beta 2-adrenergic agent, whose activation leads to an increase in intracellular adenylyl cyclase the enzyme which catalyses the conversion of adenosine triphosphate (ATP) to cyclic-3, 5 adenosine monophosphate(cAMP).
- Ipratropium bromide is an anticholinergic (parasympatholytic) agent, which inhibits vagally-mediated Reflexes by antagonizing the action of acetylcholine the transmitter agent released from the vagus nerve
- Allowing effects on both Muscarinic and beta-2 adrenergic receptor in the lungs leading to increased bronchodilation over that provided by each agent singly
- Effectively reduces hospitalisation and improves pulmonary function : "A single dose of combination therapy and multiple doses both showed reductions in the risk of hospitalisation among adults with acute asthma (Kirkland SW et al; Cochrane Database Syst Rev. 2017 Jan 11; 1. CD001284)
- Overall lung coverage due to different sites of action Ipratropium & levosalbutamol

**In.**

- ASTHMA**
- COPD**
- Chronic Bronchitis**
- Emphysema**

**For complete Lung Coverage...**

